D. Rageot

Second generation of LNP based mRNA vaccine leads to a T-cell-inflamed tumor microenvironment favorable for improving PD-1/PD-L1 blocking therapy and long-term immunity in a cold tumor model

This study shows that second-generation LNPs (Lipidots(R)) enhance antitumor immunity by remodeling the tumor microenvironment and synergizing with PD-1/PD-L1 blockade to improve therapeutic outcomes in cold tumors.